A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
41actual
Sites
2
Countries
Bulgaria, Romania
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-18 | actual | When the study began enrolling |
| Primary completion | 2025-04-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Renal Impairment
- End-stage Kidney Disease
- Healthy Participants
Intervention
- Drug: AZD4144
Primary outcomes
what the primary-completion date above is the date OFObserved maximum plasma concentration (Cmax)
measured From Day 1 to Day 14
Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf)
measured From Day 1 to Day 14
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)
measured From Day 1 to Day 14
Apparent total body clearance (CL/F)
measured From Day 1 to Day 14
Non-renal clearance of drug from plasma (CLNR/F)
measured From Day 1 to Day 14
Apparent volume of distribution based on the terminal phase (Vz/F)
measured From Day 1 to Day 14
Terminal elimination half-life (t½λz)
measured From Day 1 to Day 14
Renal clearance of drug from plasma (CLR)
measured From Day 1 to Day 4
Amount excreted (Ae)
measured From Day 1 to Day 4
Percentage of dose excreted unchanged in urine (fe)
measured From Day 1 to Day 4
Number of Treatment Emergent Adverse Events (TEAEs)
measured From Day 1 to Follow-up (Day 14/28)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed